Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is an open-label, phase II, exploratory and multi-centre clinical trial. 37 Limited stage SCLC patients not eligible for concurrent chemo-radiotherapy will be enroll. Patients will be enrolled in the trial after receiving sequential chemo-radiotherapy, if there is no progression disease, patients will be treated with maintenance Tarlatamab. Patients will receive maintenance with Tarlatamab IV until disease progression unacceptable toxicity, patient or physician decision to discontinue or death. The primary objective is to evaluate the Progression free survival (PFS). Patient accrual is expected to be completed within 2 years. Treatment and follow-up are expected to extend the study duration to a total of 5 years. Patients will be followed for 2 years after enrollment. The study will end once survival follow-up has concluded.
Eligibility Criteria
Inclusion Criteria: * Histologically or cytologically documented new diagnosis of LS-SCLC by histology or cytology from brushing, washing, or needle aspiration. Mixed tumors are not eligible. * Patients who: 1. were treated with sequential chemo-radiotherapy 2. were treated only with chemotherapy * Have at least one lesion that meets criteria for being measurable or non-measurable, as defined by RECIST 1.1. * Has completed chemo-radiation or chemotherapy alone without progression of disease per RECIST v1.1 * Be male or female ≥18 years of age inclusive, on the day of signing informed consent. * Have a life expectancy of at least 3 months from the study start. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days prior to the first dose of study intervention. * Toxicities attributed to chemo-radiotherapy treatment have to be resolved to grade ≤1, unless otherwise specified. * No clinically significant electrocardiogram (ECG) findings * Correct pu